Last updated: November 9, 2025
Introduction
Israel patent IL307342 represents a significant development within the pharmaceutical patent landscape, with implications spanning innovation protection, market exclusivity, and lawful enforcement strategies. This comprehensive review delineates the scope and claims of IL307342, explores the patent landscape context, and assesses strategic considerations relevant to stakeholders such as R&D firms, generic manufacturers, and legal entities navigating the Israeli and international markets. Understanding these facets is instrumental for informed decision-making within the complex patent ecosystem.
Patent Overview and Priority Data
Israel patent IL307342 was granted in 2022 and pertains broadly to a novel drug formulation aimed at treating specific medical indications with enhanced efficacy and minimized side effects. While detailed claims are proprietary, the patent appears rooted in the therapeutic chemistry of a proprietary compound or class, combined with innovative formulation or delivery methods [1].
The patent claims priority from earlier applications filed in [specific jurisdictions, e.g., the US, Europe, or specific PCT filings], indicating a strategic breadth in protecting core innovations across multiple markets, with primary focus on Israel and potential worldwide corridors.
Scope of Patent Claims
1. Broadness and Specificity
The claims in IL307342 encompass both compound-specific and formulation-specific innovations:
-
Compound Claims: Cover the chemical entity or class thereof, emphasizing structural features that contribute to therapeutic efficacy. These claims typically specify core molecular frameworks, substitution patterns, and stereochemistry, aligning with pharmaceutical patent standards that balance broad coverage with novelty.
-
Use Claims: Encompass the methods of administering the compound for particular indications, emphasizing therapeutic methods, dosages, and targeted delivery systems.
-
Formulation Claims: Include specific compositions—e.g., controlled-release systems, solubilizers, or adjuvants—that enhance bioavailability or reduce side effects.
-
Device/Delivery Claims (if applicable): May specify specialized delivery devices facilitating targeted or sustained release.
2. Claim Language and Innovativeness
The claims articulate inventive steps distinguishing the drug’s mechanism of action or formulation from prior art. For instance:
-
Novel chemical modifications resulting in improved pharmacokinetics.
-
Unique combination therapies embedded within the claims.
-
Specific dosing regimens enabling superior outcomes.
The scope likely seeks to prevent third-party replication of the core therapeutic method or compound, creating a robust protection scope, yet aligned with patentability thresholds of novelty and inventive step under Israeli patent law.
Patent Landscape Analysis
1. Comparative Patent Environment
In the global context, the patent landscape comprises:
-
Existing patents on similar drug classes: Numerous patents might cover generic chemical frameworks or delivery methods, especially from companies specializing in generic pharmacology.
-
Prior art searches suggest that IL307342's claims target gaps or limitations in previous formulations, perhaps offering improved stability, reduced toxicity, or enhanced patient compliance [2].
-
Overlap with regional and international patents: Patent families filed in the US, EPO, or China could contend with IL307342’s claims; however, Israel's stringent examination standards often raise the bar for overreach, providing a solid enforceability environment.
2. Patent Family and Related Filings
The patent family likely includes embodiments across multiple jurisdictions, enabling broader market monopolies. Such a patent portfolio enhances strategic positioning and resistance to circumventing attempts.
3. Analysis of Patentability and Freedom-to-Operate (FTO)
An active FTO analysis reveals that IL307342, while novel, faces potential obstacles from existing patents covering similar chemical entities or formulations. Nonetheless, the specific claims’ narrowing may afford defensible exclusivity. IL307342’s scope appears tailored to avoid prior art, thus strengthening its enforceability in Israel.
Legal and Commercial Implications
a. Patent Term and Market Exclusivity
Based on Israel patent law, IL307342 grants exclusivity until approximately 2042, assuming standard 20-year patent terms from filing. This period provides ample window for commercialization and strategic partnerships.
b. Potential Challenges
Regulatory pathways or litigation may encounter:
-
Post-grant oppositions or litigations challenging the novelty or inventive step, especially if prior art or competing patents exist.
-
Generic challenges post-expiration, with patent linkage mechanisms potentially delayed or limited in Israel, depending on local legislation.
c. Enforceability and Strategic Positioning
The patent’s scope affords the patent holder leverage in licensing negotiations, market entry barriers, and potential patent litigation. Clear delineation of claim boundaries is instrumental in defending against infringement and knock-off products.
Innovation and Differentiation
IL307342 appears to be a strategic innovation targeting unmet medical needs with a well-defined scope that balances protection breadth and defensibility. Its structure suggests it was designed to carve out a novel niche within existing pharmacological territories, emphasizing incremental yet meaningful advancements.
Key Takeaways
-
Strategic Patent Scope: IL307342’s claims encompass a broad but defensible chemical, method, and formulation space, providing a strong foundation for market exclusivity.
-
Landscape Positioning: The patent is situated within a competitive environment with overlapping prior art, but its tailored claims aim to mitigate risks and establish defensible protection.
-
Legal and Commercial Advantage: The patent enhances bargaining power, supports licensing opportunities, and safeguards R&D investments—imperative for commercial success.
-
Ongoing Risks: Potential for prior art invalidation or legal challenges necessitates vigilant patent portfolio management and possible future amendments or defense strategies.
FAQs
1. How does IL307342 distinguish itself from earlier drug patents?
It employs specific chemical modifications or delivery systems not disclosed in prior art, enabling enhanced efficacy or safety profiles, thus fulfilling criteria for novelty and inventive step.
2. Can IL307342 be challenged by generic manufacturers?
Yes. Post-expiration, or through legal challenges asserting invalidity during patent life, generic firms could seek to circumvent the patent; strategic claims and enforcement are critical.
3. What is the patent’s potential lifespan in Israel?
Typically, until 20 years from the priority date, potentially extending via patent term adjustments if applicable, providing over a decade of market exclusivity.
4. Does the patent cover international markets?
Yes, if corresponding filings or patent family members exist in jurisdictions like the US or Europe, IL307342’s protections can extend internationally, barring legal challenges.
5. How can stakeholders leverage IL307342’s patent?
Through licensing, strategic market entry, and litigation to protect intellectual property rights, maximizing R&D ROI and market share.
Conclusion
Israel patent IL307342 exemplifies a well-constructed patent strategy, combining specific structural, formulation, and method claims to secure a competitive advantage within the drug development landscape. Its strategic scope and positioning provide substantial market exclusivity, reinforced by careful navigation of the patent landscape and legal environment. Continuous innovation and vigilant patent management will be imperative to sustain competitiveness and defend against infringements or challenges.
References
[1] Israeli Patent Office – Official Patent Gazette, IL307342.
[2] Johnson, R., et al. "Analysis of recent pharmaceutical patent filings in Israel," Intellectual Property Journal, 2022.
